logo
Plus   Neg
Share
Email

Genentech: Tecentriq Fails To Meet Primary Endpoint In Phase III Study

Genentech, a member of the Roche Group (RHHBY), reported that the Phase III IMvigor010 study evaluating Tecentriq as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival compared to observation in people with muscle-invasive urothelial cancer.

Genentech noted that, in addition to ongoing Phase III studies in early and advanced bladder cancer, the company has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across genitourinary, skin,
breast, gastrointestinal, gynecological and head and neck cancers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JetBlue Airways said it will continue to block middle seats in rows where passengers are not traveling together through the July 4 holiday. JetBue will block middle seats on its Airbus aircraft, while it will block aisle seats on its smaller Embraer 190 aircraft. Customers traveling together will be allowed to sit in the middle and aisle seats. The U.S. Food and Drug Administration or FDA announced on its website that New Hoque and Sons, Inc. is recalling Radhuni Curry Powder distributed in New York City, New York due to potential Salmonella contamination. The recall was made after it was found that the finished products contained several strains of Salmonella, the company said. General Motors is reopening its plants in Mexico after it received approval from the Mexican government to restart operations in the country, according to reports. The automaker had suspended its operations in Mexico in the third week of March due to the coronavirus pandemic. GM's Mexican manufacturing facilities are important as they supply critical parts for its plants in the U.S.
Follow RTT